New drug approach for bile duct (cholangiocarcinoma) cancer
Project 2
This project tries a new drug that blocks TEAD signaling to help people with advanced bile duct (cholangiocarcinoma) cancer, alone or with chemotherapy or immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11178600 on NIH RePORTER |
What this research studies
The team is studying how the YAP-TEAD pathway helps bile duct cancer grow, resist treatment, and hide from the immune system. In the lab they use cell experiments and patient-derived tumor models to test a TEAD-blocking drug (CTX1009685) both alone and combined with standard chemotherapy or immunotherapy. Promising lab results led to a first-in-human clinical trial to study safety and signs of benefit in people with advanced cholangiocarcinoma. If you have advanced bile duct cancer, this work could open new treatment options down the line.
Who could benefit from this research
Good fit: Ideal candidates are adults with advanced or metastatic cholangiocarcinoma who have progressed on or are eligible for standard treatments and can enroll in a first-in-human trial.
Not a fit: People with early-stage disease already cured by surgery, other cancer types, or those unable to travel to the trial site or tolerate experimental therapy may not benefit.
Why it matters
Potential benefit: If successful, this approach could shrink tumors, make chemotherapy more effective, and boost the immune system's ability to attack bile duct cancer.
How similar studies have performed: Preclinical studies in cell lines and patient-derived xenograft models showed that blocking YAP-TEAD reduced tumor growth and increased chemotherapy sensitivity, but this TEAD inhibitor is now entering its first human trial.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Smoot, Rory — Mayo Clinic Rochester
- Study coordinator: Smoot, Rory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.